Vertex recently said the product may deliver more than $100 million in revenue in the 2025 full year. But it's important to ...

Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy ...

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made another round of trades on Christmas Eve, December 24, sticking ...

CRISPR Therapeutics shares early autoimmune and lymphoma data for zugo-cel, showing strong responses, manageable safety, and expanded oncology plans.

The company does possess a lot of potential, with its approved gene-editing treatment Casgevy. Unfortunately, sales from that haven't exactly been soaring, and thus its financial performance has ...

Scientists are using CRISPR to fast-track the domestication of a wild fruit. For roughly 10,000 years, farming communities ...

Earlier in the week, ARK purchased 10,353 shares of CRISPR on Wednesday, valued at $584,530, and 43,333 shares on Tuesday, totaling $2,509,414. This consistent buying pattern suggests a strong ...

A child who received the world's first personalized CRISPR therapy is now taking his first steps after months in hospital ...

Wondering if CRISPR Therapeutics is still a high risk biotech story or a quietly mispriced opportunity? This breakdown will help you decide whether the current share price makes sense for a long term ...

CRISPR biosensors enable real-time health monitoring with attomolar sensitivity, wearable integration, and multiplex ...